Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

881. Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area

Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area Sorrentino D, Paduano R, Bernardis V, Piccolo A, Bartoli E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Five types of screening programmes for colorectal cancer (CRC): annual faecal occult blood testing (FOBT), sigmoidoscopy (SIGM) (every 5 years), FOBT plus SIGM (every 1 and 5 years), colonoscopy (every 10 years) (all in the age group 55-69 years, last examination at 70 years), and 'filter' colonoscopy (FC50). The latter had to be performed in persons at 50

NHS Economic Evaluation Database.1999

882. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer

An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer Groener M G, van Ineveld B M, Byttebier G, van Hout B A, Rutten F F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two drug therapies for the treatment of advanced colorectal cancer were studied: a combination of 5-fluorouracil (5FU) and leucovorin (LV), administered as the Mayo regimen (425 mg/m^2 5-FU and 20 mg/m^2 LV for 5 days every 4-5 weeks, (5FU+LV)), and Tomudex (raltitrexed

NHS Economic Evaluation Database.1999

883. Irinotecan as second line chemotherapy in colorectal cancer

Irinotecan as second line chemotherapy in colorectal cancer Irinotecan as second line chemotherapy in colorectal cancer Irinotecan as second line chemotherapy in colorectal cancer Smithies A, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smithies A, Stein K. Irinotecan as second line chemotherapy in colorectal cancer (...) . Southampton: Wessex Institute for Health Research and Development (WIHRD) 1999 Authors' objectives To assess the effectiveness and cost-effectiveness of irinotecan as second line chemotherapy in colorectal cancer Authors' conclusions Irinotecan is a promising new agent which appears to produce small survival gains among people with advanced colorectal cancer. The evidence in its support comes from two phase III randomised controlled trials, both of which, have some methodological problems. The Committee

Health Technology Assessment (HTA) Database.1999

884. COX-2 inhibitors: a role in colorectal cancer?

COX-2 inhibitors: a role in colorectal cancer? COX-2 inhibitors: a role in colorectal cancer? COX-2 inhibitors: a role in colorectal cancer? Otten N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Otten N. COX-2 inhibitors: a role in colorectal cancer? Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien (...) de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 1999: 4 Authors' objectives To summarise the available evidence on the use of COX-2 inhibitors in the treatment or prevention of colorectal cancer. Authors' conclusions The use of ASA or NSAIDs is not recommended for the prevention of colorectal cancer as there is insufficient high quality evidence of its benefit despite numerous epidemiological and laboratory studies. Project page URL Indexing Status Subject indexing assigned

Health Technology Assessment (HTA) Database.1999

885. Colorectal cancer screening

Colorectal cancer screening Colorectal cancer screening Colorectal cancer screening Conseil d'Evaluation des Technologies de la Sante Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conseil d'Evaluation des Technologies de la Sante. Colorectal cancer screening. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS (...) ). CETS 99-2 RE. 1999 Authors' objectives This report aims to review the epidemiology and carcinogenesis of colorectal cancer, then examine the evidence regarding the efficacy of different screening strategies both for precancerous lesions and malignant lesions that are still in their early stages. Authors' conclusions CETS believes that a colorectal cancer screening program would lead to a significant reduction in the mortality due to this type of cancer. Such a program would target asymptomatic

Health Technology Assessment (HTA) Database.1999

886. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. 10615075 2000 01 06 2000 01 06 2013 11 21 0028-4793 341 27 1999 Dec 30 The New England journal of medicine N. Engl. J. Med. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. 2039-48 Two years after undergoing resection of liver metastases from colorectal cancer, about 65 percent of patients are alive and 25 percent are free of detectable (...) disease. We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection. We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone. Patients were stratified according to previous

NEJM1999

887. Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer

Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer Gastrointestinal Cancer Disease Site Group CRD summary This review assessing the role of raltitrexed in the management of metastatic colorectal cancer found that raltitrexed appears to have equivalent survival benefits to 5-fluorouracil plus leucovorin in people (...) with previously untreated colorectal cancer. The authors conclude that raltitrexed is a reasonable alternative when monotherapy with fluoropyrimidines or other thymidylate synthase inhibitors is indicated. The data presented support these conclusions. Authors' objectives To assess the role of raltitrexed in the management of metastatic colorectal cancer. Searching MEDLINE (to February 2003), Cancerlit (to October 2002), the Cochrane Library (Issue 4, 2002), the proceedings of annual meetings of the American

DARE.1998

888. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Meta-analysis Group in Cancer Authors' objectives To assess the efficacy of intravenous continuous infusion of flourouracil (...) compared with bolus administration in advanced colorectal cancer. Searching The authors searched the MEDLINE database (beginning in 1994 onwards, and going back 10 years), the proceedings of major congresses over the 10 years prior to publication of this review, and their own personal contacts with individual trial investigators. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) which accrued patients between 1984 and 1989. Treatment duration

DARE.1998

889. Follow-up of colorectal cancer: a meta-analysis

Follow-up of colorectal cancer: a meta-analysis Follow-up of colorectal cancer: a meta-analysis Follow-up of colorectal cancer: a meta-analysis Rosen M, Chan L, Beart R W, Vukasin P, Anthone G Authors' objectives To evaluate the value of intensive follow-up versus no follow-up after resection for colorectal cancer. Searching MEDLINE was searched for studies published between 1972 and 1996. A manual search of the references of retrieved articles was also conducted. Study selection Study designs (...) of evaluations included in the review Randomised trials and comparative cohort studies were included in the meta-analysis. Single cohort studies were also considered in a separate analysis. Specific interventions included in the review Intensive follow-up after resection for colorectal cancer. This included history, physical examination, and carcinoembrionic antigen values at least 3 times a year for at least 2 years. The traditional follow-up was defined as no routine follow-up and physician response

DARE.1998

890. Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer

Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer Glick S, Wagner J L, Johnson C D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Double contrast barium enema for screening for colorectal cancer within a middle age population. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population was a hypothetical population of asymptomatic males and females aged 50 entering a programme of colorectal cancer screening, who were assumed to have a 30% prevalence

NHS Economic Evaluation Database.1998

891. Faecal occult blood screening for colorectal cancer: is it cost-effective?

Faecal occult blood screening for colorectal cancer: is it cost-effective? Faecal occult blood screening for colorectal cancer: is it cost-effective? Faecal occult blood screening for colorectal cancer: is it cost-effective? Whynes D K, Neilson A R, Walker A R, Hardcastle J D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the faecal occult blood (FOB) test for colorectal cancer (CRC) screening in an unselected population of men and women aged 50 to 74 years; those in the pilot study were aged 45 to 74 years. Type of intervention Screening. Economic study type Cost-utility analysis. Study population The study population comprised unselected men and women aged 50 to 74 years; the pilot study involved

NHS Economic Evaluation Database.1998

892. Colorectal cancer screening: efficiency and effectiveness

Colorectal cancer screening: efficiency and effectiveness Colorectal cancer screening: efficiency and effectiveness Colorectal cancer screening: efficiency and effectiveness Gyrd-Hansen D, Sogaard J, Kronborg O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Using unhydrated Hemoccult (H-II) test for the colorectal cancer (CRC) screening of individuals between 45 and 75 years old every 2 years during a 10-year follow-up period. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Individuals between 45 and 75 years old. Setting Community and hospital. The economic study was carried out in Denmark. Dates to which data relate The main effectiveness data were collected between

NHS Economic Evaluation Database.1998

893. Irinotecan as second line chemotherapy in colorectal cancer (preliminary report)

Irinotecan as second line chemotherapy in colorectal cancer (preliminary report) Irinotecan as second line chemotherapy in colorectal cancer (preliminary report) Irinotecan as second line chemotherapy in colorectal cancer (preliminary report) Smithies A, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smithies A, Stein K (...) . Irinotecan as second line chemotherapy in colorectal cancer (preliminary report) Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998 Authors' objectives To provide an overview of the use of irinotecan as second line chemotherapy in colorectal cancer. Authors' conclusions There is evidence from observational studies that intravenous irinotecan given once every 3 weeks at a dosage of 350mg/m2 to patients with progressive metastatic colorectal cancer unresponsive to 5FU, exerts

Health Technology Assessment (HTA) Database.1998

894. The management of colorectal cancer

The management of colorectal cancer The management of colorectal cancer The management of colorectal cancer NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. The management of colorectal cancer. York: University of York. Effective Health Care 3(6). 1998 (...) Authors' objectives To summarise the research evidence which informed the Department of Health's Clinical Outcomes Group's guidance on commissioning cancer services, based on a series of systematic reviews. Authors' conclusions Colorectal (bowel) cancer is the second most common cause of cancer death in the UK. The disease is curable when not too far advanced and UK survival rates could be substantially improved with better management. Project page URL Indexing Status Subject indexing assigned by CRD

Health Technology Assessment (HTA) Database.1998

895. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. 9807986 1998 11 20 1998 11 20 2016 11 24 0140-6736 352 9138 1998 Oct 31 Lancet (London, England) Lancet Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. 1407-12 In phase II trials, irinotecan is active in patients with advanced colorectal cancer (...) survival in patients with advanced colorectal cancer. Rougier P P Institute Gustave Roussy, Villejuif, France. Van Cutsem E E Bajetta E E Niederle N N Possinger K K Labianca R R Navarro M M Morant R R Bleiberg H H Wils J J Awad L L Herait P P Jacques C C eng Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 0 Antimetabolites, Antineoplastic 0 Antineoplastic Agents, Phytogenic 0H43101T0J

Lancet1998

896. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. 9807987 1998 11 20 1998 11 20 2016 11 24 0140-6736 352 9138 1998 Oct 31 Lancet (London, England) Lancet Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. 1413-8 In phase II studies, irinotecan is active in metastatic colorectal cancer (...) , but the overall benefit has not been assessed in a randomised clinical trial. Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio. 189 patients were allocated irinotecan and supportive care and 90 supportive care alone. The mean age of the participants was 58.8 years; 181 (65%) were men and 98 (35%) were women

Lancet1998

897. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv 9734883 1998 09 25 1998 09 25 2015 06 16 0140-6736 351 9117 1998 Jun 06 Lancet (London, England) Lancet Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research (...) and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. 1677-81 There is conflicting evidence on the efficacy of regional adjuvant chemotherapy, via portal-vein infusion (PVI), after resection of colorectal cancer. We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (500 mg/m2 fluorouracil plus 5000 IU heparin daily for 7 days). 1235

Lancet1998

898. Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons

Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian Society of Colon and Rectal Surgeons Follow-up of patients after resection for colorectal cancer: a position paper of the Canadian Society of Surgical Oncology and the Canadian (...) Society of Colon and Rectal Surgeons Richard C S, McLeod R S Authors' objectives To evaluate the effectiveness of post-operative follow-up surveillance of patients with colorectal carcinoma. Searching [AC:The search strategy folloed the methods of the Canadian Task Force for the Periodic Health Examination]. MEDLINE was searched from 1966 to February 1996 for English and French articles using the MeSH 'colorectal neoplasm' and 'follow-up studies'. Relevant references from retrieved literature

DARE.1997

899. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies

Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies Liver Infusion Meta-analysis Group Authors' objectives To assess the effects on tumour recurrence and survival of administering fluorouracil (5-FU)-based chemotherapy by portal vein infusion (PVI) after colorectal (...) ranged from 5 to 7 days. Participants included in the review No specific inclusion criteria for the participants were stated. Participants who had undergone surgery for colorectal cancer and were enrolled in randomised controlled trials (RCTs) before 1987 were included in the review. Outcomes assessed in the review No inclusion criteria for the outcomes were stated. The outcomes of mortality, recurrence and survival rate were assessed post-operatively. How were decisions on the relevance of primary

DARE.1997

900. Participation in colorectal cancer screening: a review

Participation in colorectal cancer screening: a review Participation in colorectal cancer screening: a review Participation in colorectal cancer screening: a review Vernon S W Authors' objectives To study the prevalence, interventions to improve adherence to, predictors of adherence to, and reasons for nonadherence to faecal occult blood testing (FOBT) and sigmoidoscopy for colorectal cancer screening. Searching The following sources were searched: MEDLINE, Cancerlit and PsycINFO, all from 1973 (...) to 1996); the Social Sciences Citation Index from 1981 to 1996; and Current Contents from 1993 to 1996. The search was limited articles written in the English language. The keywords used were 'colorectal cancer', 'screening' and 'adherence'. The reference lists of the identified articles were also examined. Study selection Study designs of evaluations included in the review The studies included empirical studies that addressed one or more of the objectives. All the study designs found were included

DARE.1997